Metropolitan Life Insurance Company (MetLife)’s Supernus Pharmaceuticals SUPN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-2,615
| Closed | -$89.2K | – | 1865 |
|
|
2024
Q1 | $89.2K | Sell |
2,615
-261
| -9% | -$7.77K | ﹤0.01% | 1107 |
|
|
2023
Q4 | $83.2K | Hold |
2,876
| – | – | ﹤0.01% | 1183 |
|
|
2023
Q3 | $79.3K | Buy |
2,876
+221
| +8% | +$6.73K | ﹤0.01% | 1141 |
|
|
2023
Q2 | $79.8K | Sell |
2,655
-163
| -6% | -$5.7K | ﹤0.01% | 1142 |
|
|
2023
Q1 | $102K | Sell |
2,818
-249
| -8% | -$9.57K | 0.01% | 984 |
|
|
2022
Q4 | $109K | Buy |
3,067
+149
| +5% | +$5.18K | ﹤0.01% | 1002 |
|
|
2022
Q3 | $98.8K | Hold |
2,918
| – | – | ﹤0.01% | 1025 |
|
|
2022
Q2 | $84.4K | Hold |
2,918
| – | – | ﹤0.01% | 1166 |
|
|
2022
Q1 | $94.3K | Sell |
2,918
-10,341
| -78% | -$317K | ﹤0.01% | 1231 |
|
|
2021
Q4 | $387K | Hold |
13,259
| – | – | 0.01% | 1592 |
|
|
2021
Q3 | $354K | Sell |
13,259
-2,553
| -16% | -$68.5K | 0.01% | 1666 |
|
|
2021
Q2 | $487K | Buy |
15,812
+585
| +4% | +$17.9K | 0.01% | 1542 |
|
|
2021
Q1 | $399K | Sell |
15,227
-677
| -4% | -$18.9K | 0.01% | 1556 |
|
|
2020
Q4 | $400K | Hold |
15,904
| – | – | 0.01% | 1503 |
|
|
2020
Q3 | $331K | Hold |
15,904
| – | – | 0.01% | 1476 |
|
|
2020
Q2 | $378K | Hold |
15,904
| – | – | 0.01% | 1406 |
|
|
2020
Q1 | $286K | Hold |
15,904
| – | – | 0.01% | 1377 |
|
|
2019
Q4 | $377K | Hold |
15,904
| – | – | 0.01% | 1507 |
|
|
2019
Q3 | $437K | Hold |
15,904
| – | – | 0.01% | 1382 |
|
|
2019
Q2 | $526K | Hold |
15,904
| – | – | 0.01% | 1270 |
|
|
2019
Q1 | $557K | Hold |
15,904
| – | – | 0.01% | 1231 |
|
|
2018
Q4 | $528K | Hold |
15,904
| – | – | 0.01% | 1162 |
|
|
2018
Q3 | $801K | Hold |
15,904
| – | – | 0.01% | 1057 |
|
|
2018
Q2 | $952K | Buy |
15,904
+187
| +1% | +$9.69K | 0.02% | 946 |
|
|
2018
Q1 | $720K | Hold |
15,717
| – | – | 0.01% | 1062 |
|
|
2017
Q4 | $626K | Sell |
15,717
-15,581
| -50% | -$616K | 0.01% | 1132 |
|
|
2017
Q3 | $1.25M | Sell |
31,298
-2,388
| -7% | -$103K | 0.01% | 1125 |
|
|
2017
Q2 | $1.45M | Hold |
33,686
| – | – | 0.01% | 1066 |
|
|
2017
Q1 | $1.05M | Sell |
33,686
-1,117
| -3% | -$29.9K | 0.01% | 1206 |
|
|
2016
Q4 | $879K | Hold |
34,803
| – | – | 0.01% | 1363 |
|
|
2016
Q3 | $861K | Hold |
34,803
| – | – | 0.01% | 1366 |
|
|
2016
Q2 | $709K | Buy |
34,803
+4,670
| +15% | +$82.8K | 0.01% | 1470 |
|
|
2016
Q1 | $460K | Buy |
30,133
+7,162
| +31% | +$93.4K | ﹤0.01% | 1626 |
|
|
2015
Q4 | $309K | Hold |
22,971
| – | – | ﹤0.01% | 1940 |
|
|
2015
Q3 | $322K | Sell |
22,971
-2,303
| -9% | -$42.8K | ﹤0.01% | 1935 |
|
|
2015
Q2 | $429K | Buy |
25,274
+1,554
| +7% | +$22.1K | ﹤0.01% | 1849 |
|
|
2015
Q1 | $287K | Hold |
23,720
| – | – | ﹤0.01% | 1868 |
|
|
2014
Q4 | $197K | Hold |
23,720
| – | – | ﹤0.01% | 2422 |
|
|
2014
Q3 | $206K | Hold |
23,720
| – | – | ﹤0.01% | 2346 |
|
|
2014
Q2 | $260K | Buy |
+23,720
| New | +$211K | ﹤0.01% | 2320 |
|
Other funds holding SUPN
AC
PCH
SIMG
Metropolitan Life Insurance Company (MetLife)'s SUPN Position: Q2 2024 in Review
Metropolitan Life Insurance Company (MetLife) sold out of Supernus Pharmaceuticals (SUPN) in Q2 2024, closing a stake of 2,615 shares — an estimated $89.2K sold.
Metropolitan Life Insurance Company (MetLife) first reported a position in SUPN in Q2 2014 and held it in 40 quarters. The position peaked at $1.45M in Q2 2017. 245 funds tracked by Wall St. Rank hold SUPN as of Q2 2024.
- Metropolitan Life Insurance Company (MetLife) reported no remaining Supernus Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
- Metropolitan Life Insurance Company (MetLife) sold 2,615 Supernus Pharmaceuticals shares in Q2 2024, an estimated $89.2K.
- Metropolitan Life Insurance Company (MetLife) first reported a position in Supernus Pharmaceuticals in Q2 2014 and held it in 40 quarters.
- Metropolitan Life Insurance Company (MetLife)'s Supernus Pharmaceuticals position peaked at $1.45M in Q2 2017.
- 245 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2024.
Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q2 2024, filed 13 Aug 2024.